Research Applications for Striatech Products

Traumatic Brain Injury (TBI)

Mechanical, blast, and closed-head injury producing primary axonal damage and a delayed cascade of neuroinflammation and neurovascular disruption. Visual deficits are reported by 30–70% of survivors yet often missed by standard acuity tests.
Introduction

What is Traumatic Brain Injury (TBI)?

Traumatic brain injury (TBI) encompasses a heterogeneous spectrum of acute CNS insults caused by external mechanical forces – blunt impact, closed-head inertial loading, blast overpressure, and controlled cortical deformation. The unifying feature is a primary mechanical injury followed by a secondary cascade of neuroinflammation, excitotoxicity, oxidative stress, and neurovascular disruption that evolves over hours to weeks. Because the optic nerve is CNS white matter and the retina is an accessible outpost of the brain, the visual system is among the most measurable downstream targets of TBI pathophysiology. Clinical data consistently show that 30 to 70 per cent of TBI survivors – including military personnel with blast exposure, athletes with sports concussion, and patients with closed-head motor-vehicle injuries – report persistent visual complaints, ranging from contrast sensitivity loss and photophobia to convergence insufficiency and oculomotor dysfunction. Yet standard clinical visual acuity measurements often appear normal even in symptomatic patients, underscoring the need for sensitive, objective functional endpoints. This page focuses specifically on TBI-associated visual pathway damage at the intersection of Trauma and Acute Injury and Ocular Inflammation and Immune-Mediated Eye Disease. The emphasis is on mechanisms specific to the visual system, including indirect mechanical coupling from the skull to the optic nerve and retina, blast-induced pressure wave effects, and systemic immune responses that drive retinal pathology remote from the primary injury site. Broader context on acute CNS injury models and inflammatory mechanisms is provided here: Trauma and Acute Injury, Ocular Inflammation and Immune-Mediated Eye Disease.
Vision: A Window into the brain 

Why Are Visual Endpoints Relevant in Traumatic Brain Injury (TBI) Research?

TBI is primarily a brain injury, yet the visual system provides some of the most tractable non-invasive readouts of CNS damage severity and recovery trajectory. The retina and optic nerve are embryologically derived from the diencephalon and share the cellular machinery and vulnerability profiles of central white matter tracts. Retinal ganglion cells (RGCs) – whose axons form the optic nerve – are especially sensitive to the secondary injury cascade after TBI: axonal stretch injury, inflammatory cytokine exposure, and microvascular disruption all converge on the RGC layer within hours to days of impact or blast. Because the retina can be imaged non-invasively and because the optomotor reflex (OMR) provides a stimulus-driven behavioural readout of retino-subcortical pathway integrity, visual function endpoints serve as real-time windows into brain injury biology. For researchers whose primary focus is not the visual system – TBI neurobiologists, blast injury pharmacologists, neurotrauma engineers – this matters because visual acuity and contrast sensitivity measured by the optomotor reflex correlate with both the magnitude of the initial insult and the efficacy of neuroprotective interventions. A treatment that preserves RGC function after blast TBI is demonstrating CNS neuroprotection, not merely an ocular effect. The retinal inflammatory response after TBI also mirrors and is mechanistically linked to neuroinflammatory cascades in the hippocampus, cortex, and subcortical visual pathways: blocking IL-1 signalling in the retina after blast injury, for instance, attenuates both retinal microglial activation and optic nerve axonal damage, providing a readily accessible pharmacodynamic readout for treatments targeting central neuroinflammation. For broader context on how neuroinflammatory amplification affects visual pathways, see Neuroinflammation.
Animal Models

What Are Common Animal Models For Traumatic Brain Injury (TBI)?

The models below have documented direct evidence for visual system involvement in the cluster-specific context of TBI – meaning retinal, optic nerve, or subcortical visual pathway pathology has been characterised as a downstream consequence of the head or brain injury, rather than as a direct ocular insult.
  • Blast-mediated TBI (shock-tube model, murine) – The most extensively characterised model for TBI visual system research in this corpus. A pressurised shock tube delivers defined overpressure waves (typically 20-30 PSI) to the restrained mouse head, producing closed-globe ocular injury and retinal pathology through a combination of direct pressure-wave coupling and secondary immune-mediated mechanisms. Harper et al. (2022, 2024) used this model with OptoDrum to document OMR deficits correlating with microglial activation, cytokine upregulation, and dose-dependent RGC loss. For a comparison of blast versus blunt injury pathologies, external literature demonstrates divergent patterns of unilateral versus bilateral optic tract degeneration.
  • Controlled cortical impact (CCI) – A pneumatic piston delivers a defined cortical deformation over an open craniotomy. The model produces reproducible graded injury in the visual cortex and subcortical white matter, and has been used by multiple groups to demonstrate contrast sensitivity deficits, reduced ERG b-wave amplitude, and optic nerve axonal degeneration correlating with injury severity. Raloxifene-mediated microglial inhibition has been shown to reduce CCI-induced visual deficits in this model. CCI is the standard model for moderate-to-severe focal TBI with visual cortical involvement.
  • Closed-head impact (weight-drop / CHIMERA) – Weight-drop models (e.g., Marmarou model) and the Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA) produce diffuse axonal injury without craniotomy. Visual consequences documented in external literature include impaired visual cliff performance, decreased VEP amplitude, and optic nerve GFAP upregulation. These models are particularly relevant for mild-to-moderate repetitive TBI contexts (sports concussion, occupational exposure).
  • Fluid percussion injury (FPI) – Lateral or midline FPI via a fluid-filled cylinder produces diffuse axonal shear injury and is frequently used for moderate TBI modelling. Visual pathway deficits including RNFL thinning and optic tract degeneration have been documented, with laterality differences between midline and lateral injury consistent with expected ipsilateral versus contralateral pathway involvement.
If fewer than three models are listed for any specific sub-context (e.g., indirect traumatic optic neuropathy as a peripheral extension), researchers should consult the full model landscape on Trauma and Acute Injury and Optic Nerve Damage for additional model options.
Research Questions

How Can Striatech Tools support Your Study?

Select a question that matches your research objective to see which instruments are relevant, what challenge they address, and what the published evidence shows.
01
Can Optomotor Testing Detect Dose-Dependent Visual Deficits Before Structural Damage Appears in Blast-TBI Models?
Audience A - Vision-focused

Quick Answer

Yes. In a murine shock-tube blast model, OptoDrum detected visual acuity deficits at 16 weeks post-injury at moderate blast doses (20 PSI) at which retinal thickness and RGC counts were not yet significantly different from sham animals. Higher blast intensity (30 PSI x 3) produced earlier deficits visible by 1 week and was associated with regional RGC loss; but at lower doses the OMR assay provided the only objective evidence of functional impairment, demonstrating that non-invasive behavioural visual testing captures sub-clinical retinal circuit damage that structural histology misses in its early phase.

The challenge

A persistent methodological problem in blast-TBI research is determining whether a given exposure has produced functionally meaningful retinal damage. Histological RGC counts and retinal thickness measurements by OCT require either terminal sacrifice or specialised imaging infrastructure, and they frequently appear normal at early and moderate injury levels. VEP and ERG are informative but require anaesthesia, specialised electrode placement, and operator expertise, constraining longitudinal throughput. At the same time, clinical data in blast-exposed veterans and in mild TBI populations show that patients report significant visual disturbance – contrast sensitivity loss, photophobia, reading difficulty – even when standard clinical acuity tests are normal, suggesting that the damage occurring at sub-structural thresholds is real and functionally important. A dose-response assay capable of repeated measurement without anaesthesia or sacrifice, and sensitive enough to register deficits before structural endpoints, would directly address this gap. Repetitive mild TBI adds further complexity: multiple low-level blast exposures may compound over time, and distinguishing cumulative from single-hit effects requires time-series data from the same animals. Without a repeatable, non-invasive functional endpoint, cumulative drift cannot be tracked within-subject.

How Striatech products help

OptoDrum
Measures spatial visual acuity (cycles per degree) and contrast sensitivity threshold via the subcortical optomotor reflex in awake, freely moving mice. Non-invasive, repeatable within the same animal across multiple time points without anaesthesia or sacrifice, enabling longitudinal dose-response tracking of visual decline after blast or impact TBI.
Non-aversive Animal Platform
Minimises handling stress during OMR testing, which is especially relevant when blast- or impact-injured animals may have heightened stress reactivity or when repeated measurements are required across many post-injury time points.
DarkAdapt
Provides a controlled dark-adaptation environment prior to scotopic OMR testing with the ScotopicKit, relevant when rod pathway sensitivity is of interest after blast injury (dark-adaptation kinetics and scotopic contrast sensitivity are candidate early injury biomarkers).

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Harper et al (2024) Exp Eye Res.
    OptoDrum measured visual acuity and contrast sensitivity in mice receiving 20 PSI x1, 20 PSI x1 (repeated), and 30 PSI x3 blast exposures at 1-, 4-, and 16-week intervals. OMR deficits were detected at 16 weeks in the 20 PSI group in the absence of significant changes in retinal thickness or RGC density, demonstrating functional sensitivity exceeding structural endpoints at this dose. The 30 PSI x3 group showed OMR deficits by 1 week alongside regional central-retinal RGC loss, establishing a dose-response gradient from functional-only to structural-plus-functional impairment.
  • Morriss et al. (2021) J Neurotrauma.
    ERG and VEP were measured in a repetitive mTBI model. VEP amplitude was significantly reduced (p = 0.0007) while ERG changes were minimal (only oscillatory potential OP3 was affected), indicating that signal transmission deficits occurred primarily distal to the retina. This dissociation between ERG and VEP is consistent with sub-retinal (optic nerve and white matter) involvement and complements the OptoDrum OMR readout, which captures the retino-subcortical pathway as a unit. Note: this study used institutional electrophysiology apparatus; OptoDrum implements the subcortical OMR endpoint in a standardised, automated format.
  • Orbach et al. (2024) J Neurotrauma.
    Spatial frequency and contrast sensitivity were reduced in ipsilateral eyes of mice exposed to blast in enclosed chambers; contralateral eyes showed differential effects depending on holder design. Weight-drop-induced TBI also produced decreased ERG evoked potential and RGC loss. This study confirms that preclinical optomotor and electrophysiological endpoints translate across multiple mild-TBI model types.
02
What Retinal Immune Responses Follow Blast-Mediated TBI, and How Does Neuroinflammatory Amplification Drive Functional Visual Loss?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Blast-mediated TBI triggers rapid upregulation of retinal IL-1β, IL-1α, TNFα, and IL-6 within hours of injury, accompanied by microglial hyperactivation and Muller glia reactivity. These inflammatory changes correlate directly with functional visual deficits measured by the optomotor reflex. Critically, systemic immune cells activated by TBI can autonomously drive RGC dysfunction and death even in the absence of ongoing direct ocular trauma – demonstrating that peripheral immune activation is a distinct pathogenic arm of blast-TBI retinal damage. Blockade of the IL-1 pathway with anakinra partially rescues OMR function, validating the inflammatory mechanism as a therapeutic target.

The challenge

Understanding why TBI causes visual dysfunction requires disentangling at least three injury mechanisms: direct mechanical coupling of the blast wave or impact to the globe and optic nerve; local retinal inflammatory responses activated by the initial mechanical insult; and systemic immune activation – including T-cell and cytokine-mediated signalling – that reaches the retina through a disrupted blood-retinal barrier. These mechanisms are not mutually exclusive and interact over time. For preclinical researchers designing therapeutic interventions, distinguishing the immune-mediated component from the structural-mechanical component is essential because these arms may have distinct therapeutic windows and targets. Retinal microglia, once activated by blast-induced RGC damage, enter a self-sustaining activation loop: pro-inflammatory cytokines (IL-1β, TNFα) amplify local neurodegeneration, and Muller glia activation extends GFAP immunoreactivity across the full retinal depth, signalling ongoing retinal stress. This neuroinflammatory amplification represents a secondary injury phase that may be more tractable therapeutically than the primary mechanical insult. An endpoint that tracks functional retinal circuit integrity non-invasively – rather than requiring repeated terminal histology to quantify microglial density or cytokine levels – would enable longitudinal testing of anti-inflammatory interventions in the same animals. For the broader framework of how neuroinflammatory mechanisms drive visual pathway damage, see Neuroinflammation and Ocular Inflammation and Immune-Mediated Eye Disease.

How Striatech products help

OptoDrum
Tracks optomotor reflex-based visual acuity and contrast sensitivity longitudinally in the same animals across the post-blast inflammatory time course (acute: hours to days; subacute: 1-4 weeks; chronic: months), enabling functional monitoring of the neuroinflammatory injury phase and quantification of rescue by anti-inflammatory interventions. Subcortical OMR is directly driven by retino-recipient pathway integrity and is not confounded by cortical state or anaesthesia effects.
AcuiSee
Measures cortical visual acuity via operant visual-reward discrimination, which is appropriate when higher visual cortical involvement in TBI (visual cortex contusion, retrograde degeneration of thalamocortical projections) is the mechanistic focus, or when suprathreshold visual perception is the therapeutic outcome of interest.
Non-aversive Animal Platform
Reduces handling stress in post-TBI animals, which may have altered HPA axis reactivity; stress reduction minimises corticosterone-mediated confounding of the inflammatory readout during longitudinal measurement sessions.

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Harper et al (2022) Exp. Eye. Res.
    Blast-induced immune activation, including adoptive transfer of splenocytes from blast-exposed mice into naive mice produced RGC dysfunction and death in the recipient animals, demonstrating that circulating immune cells activated by TBI can autonomously damage the retina. OMR-based visual acuity (OptoDrum) measured post-transfer confirmed the functional consequence of this systemic-to-retinal immune signalling pathway.
  • Evans et al. (2020), J Neurotrauma.
    Triple blast exposure in mice increased retinal IL-1β, IL-1α, TNFα, and IL-6 mRNA within 4 h, alongside IBA-1+ microglial activation and GFAP+ Muller glia reactivity. IL-1 receptor blockade with anakinra partially rescued PERG amplitude and preserved RGC complex thickness at 4 weeks. Note: PERG was the measurement instrument used in this study; Striatech's OptoDrum captures RGC pathway-level functional output via the subcortical OMR, providing a complementary non-invasive endpoint for this same pharmacological question.
  • Au et al. (2022) Front Immunol.
    Review of microglial activation after optic nerve injury: activated microglia adopt amoeboid morphology, phagocytose dying RGCs, produce pro-inflammatory cytokines (IL-1β, IL-6, TNFα, iNOS), and enter a self-amplifying neurotoxic M1 phenotype that persists for months after injury. Blood-retinal barrier disruption exacerbates RGC loss by permitting peripheral leukocyte infiltration. Note: this review used optic nerve crush as its primary model; the mechanistic framework is directly applicable to blast-TBI neuroinflammation, where the initiating event differs but the downstream microglial activation cascade is analogous.
03
Why Are Retinal Ganglion Cells and the Optic Nerve Especially Vulnerable After Closed-Head and Blast TBI – Even Without Direct Ocular Impact?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Retinal ganglion cells and optic nerve axons are selectively vulnerable to closed-head and blast TBI through at least three mechanisms acting in the absence of direct ocular impact: (1) inertial strain transmitted through the skull base to the optic canal, producing shear stress at the point where the optic nerve is tethered to bone; (2) intracranial pressure transients that propagate retrograde along the optic nerve sheath; and (3) systemic and local inflammatory cascades that converge on the highly metabolically active RGC soma and proximal axon. This constellation constitutes indirect traumatic optic neuropathy (ITON), which accounts for a substantial proportion of post-TBI visual loss in both humans and rodent models.

The challenge

Indirect traumatic optic neuropathy is clinically under-recognised because the optic disk appears normal acutely – pallor and atrophy develop only weeks later – and standard visual acuity testing may be insensitive to early functional decline. Approximately 50 per cent of ITON patients present with immediate severe vision loss despite a normal-appearing optic disk, while a further 10 per cent deteriorate in the subsequent weeks. In rodent models, the spatial pattern of optic nerve degeneration after blast TBI differs from that after blunt TBI: single-blast injury produces predominantly unilateral contralateral optic tract degeneration, while midline blunt TBI produces bilateral optic nerve injury, reflecting the different biomechanical coupling mechanisms. Distinguishing these patterns preclinically requires not just histological tract tracing but functionally lateralised visual endpoints. The optomotor reflex, while integrated across both eyes via the subcortical accessory optic system, provides a sensitive system-level readout of the RGC-optic nerve circuit and can reveal deficits whose anatomical substrate can then be confirmed by immunohistochemistry, OCT, or axon-count histology. Visual cortex function – measurable via cortical VEP or operant acuity tasks – provides a complementary downstream endpoint when suprathreshold cortical visual processing is of interest. For the broader context of RGC degeneration mechanisms and structural endpoints, see Retinal Ganglion Cell Pathology and Optic Nerve Damage. For axonal degeneration in post-TBI optic nerve, see Axon Degeneration.

How Striatech products help

OptoDrum
Measures the subcortical OMR driven by the retina-to-accessory-optic-system pathway; captures functional integrity of the RGC-optic nerve axis non-invasively. Can reveal lateralised deficits by testing each eye independently (clockwise vs. counterclockwise grating rotation), providing a behavioural correlate of the asymmetric optic tract degeneration documented after blast versus blunt TBI.
AcuiSee
Operant cortical visual acuity endpoint – appropriate for assessing downstream cortical visual processing when the primary question concerns suprathreshold visual discrimination or when visual cortical involvement (contusion, retrograde thalamocortical degeneration) is mechanistically relevant. Complements OptoDrum's subcortical OMR readout.

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Hetzer et al. (2024) Exp Neurol.
    Both blunt impact and blast-inertial injury produced comparable OMR deficits (assessed by optokinetic response testing), but blunt neurotrauma induced bilateral optic tract degeneration while blast injury produced unilateral contralateral degeneration. RGC loss was comparable across both methods and severities, suggesting that a single-hemisphere insult is sufficient to drive bilateral RGC death. Note: this study used a custom optokinetic apparatus; Striatech's OptoDrum implements the same subcortical reflex endpoint in a standardised, automated format.
  • Bernardo-Colón et al. (2019) Front. Neurosci.
    Approximately 50 per cent of ITON patients present with immediate severe vision loss despite a normal optic disk; optic disk pallor develops at 4-6 weeks. In the air-blast mouse model, repeated low-level blast damages the optic nerve while sparing photoreceptors, and a 20 per cent transient IOP elevation was observed – a glaucoma-relevant finding. The mechanistic distinction between ITON and direct traumatic optic neuropathy (proximal-to-distal axon degeneration in ITON vs. distal-to-proximal in direct injury) is relevant to therapeutic targeting.
  • Lyons et al. (2024), Eye.
    Eye Consistent longitudinal RNFL thinning after mTBI, with clinically meaningful correlations between RNFL thinning and visual acuity or visual field patterns. Forty-three to 47 per cent of patients had visual field deficits at 3-12 months post-injury. OCT RNFL is proposed as a biomarker for mTBI visual pathway involvement; functional endpoints including VEP and contrast sensitivity provide complementary performance-based biomarkers. Note: these are human clinical data; preclinical OMR testing operationalises the functional endpoint in rodent models.
04
How Can Longitudinal Visual Function Measurements Serve as Outcome Biomarkers for Post-TBI Recovery and Therapeutic Intervention Windows?
Audience A - Vision-focused

Quick Answer

The temporal profile of visual acuity and contrast sensitivity decline after TBI follows a biphasic pattern in rodent models – an acute phase in the first days to week, a potential partial recovery window, and a chronic secondary degeneration phase extending weeks to months. Non-invasive repeated OMR measurements in the same animals enable within-subject tracking of this trajectory without sacrificing animals for structural endpoints at each time point, identifying both the trough of functional loss and the duration of the therapeutic window during the secondary inflammatory phase.

The challenge

The natural history of post-TBI visual dysfunction in rodent models is not uniform: a biphasic ERG pattern has been documented in blast-injured mice, with an acute loss recovering within 24 hours of blast, followed by a chronic loss appearing at 4 months post-blast. Similarly, OMR deficits measured at 16 weeks post-blast in the Harper et al. (2024) dose-response study were absent at earlier time points in the lower-intensity group, suggesting progressive secondary degeneration rather than immediate loss. Identifying the inflection point between primary damage and secondary amplification is critical for defining the therapeutic window – the period during which anti-inflammatory, neuroprotective, or neuroregenerative interventions are most likely to succeed. Terminal histology – RGC counting by immunohistochemistry, RNFL thickness by OCT – provides only cross-sectional snapshots and requires different cohorts at each time point. This design inflates cohort sizes and prevents within-subject comparison of the functional trajectory. Non-invasive, repeatable OMR measurements address this directly: the same mouse can be tested at 1 day, 1 week, 4 weeks, and 16 weeks post-injury, yielding a personalised trajectory that captures both the timing and magnitude of visual decline. This longitudinal design also enables statistical matching of functional endpoints to subsequent terminal histological findings in the same animal.

How Striatech products help

OptoDrum
Repeatable, non-anaesthetic optomotor acuity and contrast sensitivity measurements enable within-subject longitudinal profiling of visual decline and recovery after TBI. Automated staircase paradigm minimises operator-dependent variability across time points. Multiple measurements per session provide threshold estimates with defined confidence.
ScotopicKit
Extends OMR testing to scotopic conditions, enabling separate assessment of rod-pathway-dependent dark-adapted contrast sensitivity as a distinct post-TBI visual endpoint. Rod pathway integrity may be differentially affected by blast versus impact injury.
DarkAdapt
Standardised dark-adaptation chamber ensures consistent pre-test conditions for scotopic OMR measurements across longitudinal sessions.
AcuiSee
Operant cortical visual discrimination – relevant when the longitudinal question includes cortical visual recovery (e.g., after CCI involving the visual cortex) as a distinct endpoint from the subcortical OMR trajectory.

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Mohan et al. (2013) Invest Ophthalmol Vis Sci.
    Pattern ERG in blast-injured mice showed a biphasic profile: acute pERG amplitude reduction at 24 hours post-blast recovering by day 1, and a chronic pERG decrease appearing at 4 months post-blast; RNFL thinning was detected by OCT at 3 months. This biphasic time course – acute functional loss, partial recovery, chronic re-emergence – defines the longitudinal monitoring paradigm for which repeated non-invasive OMR is particularly suited. Note: pERG was used as the functional endpoint in this study; OptoDrum's subcortical OMR provides a complementary non-invasive behavioural correlate.
  • Kim et al. (2024) BMC Ophthalmol.
    Optic chiasm volume in TBI patients was significantly larger than controls from 3 to 12 months post-injury; this chiasm swelling at 3 months negatively correlated with processing speed index at 12 months, suggesting that structural visual pathway changes in the sub-chronic phase predict later cognitive outcomes. This translational finding supports the use of visual pathway biomarkers as predictors of longer-term CNS recovery trajectory.
  • Rasdall et al. (2025) JAMA Ophthalmol.
    In 28 mild TBI patients, 78 per cent had deficits in oculomotor function and/or primary visual pathway measures. Contrast sensitivity was significantly reduced (p = 0.04) and VEP binocular summation index was increased (p = 0.02), even in patients without self-reported visual symptoms. Machine learning detected subtle visual pathway differences independent of symptom reporting. This epidemiological pattern – widespread subclinical visual dysfunction in mTBI – motivates sensitive preclinical endpoints like OMR for translational model validation.
Product Fit

Summary: Striatech Products supporting your research questions

Research Question / Application OptoDrum ScotopicKit AcuiSee Photorefractor Keratometer DarkAdapt Non-aversive platform
Blast TBI dose-response / early functional detection Yes Yes
Neuroinflammatory visual pathway damage / rescue Yes Yes Yes
RGC and optic nerve vulnerability (ITON) Yes Yes
Longitudinal recovery trajectory / therapeutic window Yes Yes Yes Yes Yes
Measurement Modalities

Measuring Functional Visual Outcomes in Traumatic Brain Injury (TBI): How Do Available Methods Compare?

Modality Invasiveness Repeatability in Same Animal Anaesthesia Required Automation What It Measures 3Rs Impact
OptoDrum (OMR) None High – unlimited sessions No Fully automated staircase Spatial acuity and contrast sensitivity via subcortical reflex; retina-to-brainstem pathway Reduces cohort sizes through longitudinal within-subject design; no sacrifice required
AcuiSee (operant) None High – training required initially No Automated operant chamber Cortical visual acuity via learned discrimination; requires visual cortex Reduces cohorts; longer per-animal training time
VEP Low (scalp electrode) Moderate – technically demanding session-to-session Yes (typically) Partial – signal analysis is standardised Cortical visual evoked potential; optic nerve conduction to V1 Moderate cohort size; anaesthesia is a repeated stressor
ERG (pattern or flash) Low (corneal contact lens) Moderate Yes Partial Retinal function (b-wave, PhNR for RGCs); does not assess optic nerve or cortical pathway Anaesthesia stress; useful complement for separating retinal from post-retinal deficits
OCT (RNFL, RGC complex) Low (topical anaesthesia, dilation) High Light sedation or restraint Semi-automated segmentation Structural retinal layer thickness; does not measure function Detects structural loss only after significant cell death; functional OMR precedes OCT changes at low TBI doses
RGC histology (IHC, flat mount) Terminal None – single time point per animal Terminal anaesthesia Manual counting or semi-automated RGC density, morphology, axon number High animal use; longitudinal tracking requires separate cohorts per time point
OptoDrum and AcuiSee are complementary within TBI research: OptoDrum captures the retino-subcortical OMR pathway (the primary readout for retinal and optic nerve injury), while AcuiSee captures cortical visual acuity (appropriate when visual cortex contusion or thalamocortical disruption is the mechanistic focus). VEP and ERG provide electrophysiological depth to separate retinal, optic nerve, and cortical contributions to visual loss; histology confirms the structural substrate. An integrative longitudinal design would use OptoDrum for repeated non-invasive screening, VEP or AcuiSee to probe cortical involvement at selected time points, and terminal histology to confirm RGC and axon counts at study end.
Supported by Striatech Products

Publications on Traumatic Brain Injury (TBI)

Keep exploring

Related application areas, neighbouring research chapters, and the questions researchers ask most.

Application Area

Traumatic Brain Injury (TBI)

Mechanical, blast, and closed-head injury producing primary axonal damage and a delayed cascade of neuroinflammation and neurovascular disruption. Visual deficits are reported by 30–70% of survivors yet often missed by standard acuity tests.

1
Research Chapters
4
FAQs answered
Main Field where Traumatic Brain Injury (TBI) is studied
CNS Trauma and Acute Injury: TBI, Optic Nerve Injury, Stroke